The multi-disciplinary engineering consultancy NIRAS has released a new report highlighting AI as a “strategic necessity”.
However, it also warns that leaders must “separate hype from actionable opportunity”.
In the report, ’Harnessing AI in GxP Environments: Innovation, compliance & trust’, experts from NIRAS outline a strategic playbook for pharma and life science managers to unlock the huge potential of implementing AI with trust, transparency and traceability from the start.
The integration of AI into GxP-regulated environments offers opportunities to enhance compliance, quality and productivity.
However, the report also warns about the risks of poor data quality, the suitability of black-box AI models for GxP applications and the challenges of ongoing updates and recalibration.
Commenting on the analysis, Jesper Madsen Wagner, expert director at NIRAS, said: “The pharma and life sciences industry is entering an era which will be shaped by AI and digital transformation."
"For the industry to navigate this shift, executive leadership must take a proactive role in determining how these technologies are adopted.
“There’s no doubt that AI is set to transform pharma and life science value chains, but in GxP-regulated environments, innovation must be as disciplined as it is disruptive."
"It’s vital that leadership is equipped to separate hype from actionable opportunity."
“The main message is clear: AI’s future in pharma & life science belongs to leaders who incorporate trust, transparency and traceability from the get-go.”